Genmab — Februar 2025
-
https://ml-eu.globenewswire.com/Resource/Download/1983b06a-a728-4821-b46e-92d770b79cf0 Genmab påtænker, at aflyse 2 mio aktier (nedskrive kapitanen). Bemyndiges til at købe op imod 10% af kapitalen tilbage (buy back). At pålægge bestyrelse kun at sælge aktier til at dække skattebetaling !!!
-
Hvis JnJ ikke udnytter sin option på CD38 har Genmab så ikke mulighed for at sælge den til andre? Eller vurderes det at kvaliteten ikke er hensigtsmæssig hvis JnJ ikke vil udnytte optionen.
-
Leerink analyst Jonathan Chang upgraded Genmab (GMAB) to Outperform from Market Perform with a $27 price target, citing a longer-term view beyond the near-term Johnson & Johnson (JNJ) opt-in decision for GEN3014. The firm continues to believe it is unlikely that J&J will opt-in. However, at current stock levels, Leerink thinks that thesis is already largely baked in. Further, the firm believes that current stock levels reflect low investor expectations on this upcoming catalyst expected in Q1
-
2025, which aligns with its view. Leerink sees current levels as attractive with a longer-term view given Genmab’s track record of success and the potential of its late-stage pipeline programs. While the near-term GEN3014 update may introduce volatility in the stock, its long-term outlook for the stock at these levels is positive.
-
Er det mig eller lyder det som om, at pkt 7c og 7d i agendaen for generalforsamlingen modarbejder hinanden??
-
Begrænse, men vil samtidig købe aktier?
-
Hvis de alligevel vil sælge ud inden årets udgang af skattemæssige grunde, så kommer der jo blot en ny kurs-nedtur senere på året.
-
Troede vi havde med et medico-selskab at gøre og ikke et invest/skattespekulations-selskab
-
Forstår ikke, hvad du undrer dig over. Punkt
De vil annullere de aktier, de har tilbagekøbt. Punkt d: De vil tilbagekøbe flere aktier. Begge bidrager til, at hver aktie vil repræsentere en større del af virksomheden. -
Genmab/Leering: Hæver til "outperform" fra "market perform" https://proinvestor.com/investornyt/1277877/genmab-leering-haever-til-outperform-fra-market-perform
-
Genmab får skåret kursmål for notering i USA af amerikansk børshus https://proinvestor.com/investornyt/1277895/genmab-far-skaret-kursmal-for-notering-i-usa-af-amerikansk-borshus
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind